Endocrinology, Diabetes & Metabolism Doctors in Traverse City, MI Accepting Medicare

4 Endocrinology, Diabetes & Metabolism doctors found. Showing 1 - 4

Dr. Jill Elizabeth Vollbrecht, MD Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 5015 N Royal Dr, Traverse City, MI 49684 Phone: 231-935-0850    Fax: 231-935-0850

John E Brunner, M.D. Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 1221 Sixth St Ste 208, Traverse City, MI 49684 Phone: 231-935-2045    Fax: 231-935-3420

Karla Kay Giese, CFNP Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1221 Sixth St Ste 208, Traverse City, MI 49684 Phone: 231-935-2045    Fax: 231-935-3420

Dr. Mary Eleanor Beal, M.D. Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 3837 W. Front St, Suite H, Traverse City, MI 49684 Phone: 231-935-8878    Fax: 231-935-8901

News Archive

Positive short term results from combined surgical and electrophysiological approach to treat AF

nContact Surgical, Inc., a leader in the investigation of devices for minimally-invasive treatment for heart conditions, announced that data from a poster was presented at the American Heart Association Scientific Sessions in Orlando. The study demonstrated that the convergent approach, which combines surgical and electrophysiological expertise, appears to be a good strategy to achieve short term success in patients with long standing persistent atrial fibrillation (AF).

MGC Diagnostics' total revenues grow 24.9% to $37.5 million in fiscal year 2015

MGC Diagnostics Corporation, a global medical technology company, today reported financial results for the fourth quarter and the fiscal year 2015, ended October 31, 2015.

Sleep - a big part of memory and learning

Memorizing a series of facts is one thing, understanding the big picture is quite another.

Combination regimen shows promising results in preclinical models of triple negative breast cancer

Tumor volume in a preclinical model of triple negative breast cancer (TNBC) was reduced four times more when an experimental polo-like kinase 1 (PLK1) inhibitor was combined with a standard-of-care chemotherapeutic agent than when the agent was used alone.

Read more Medical News

› Verified 8 days ago